← Back to headlines
Summit Therapeutics Announces FDA PDUFA Date for Ivonescimab
Summit Therapeutics has outlined November 14 as the FDA PDUFA date for its ivonescimab Biologics License Application (BLA) and plans for HARMONi-3 PFS in the second half of 2026.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
Volkswagen Approves Major Restructuring Plan Targeting 100,000 Jobs
28m ago
Trump Administration Seeks Supreme Court Approval for Mail Ballot Restrictions
51m ago
New US-Venezuela Oil Agreement Draws Sharp Criticism and Economic Skepticism
52m ago
Crusoe Secures $3 Billion Funding and Lands $13 Billion Cloud Deal
56m ago